Effects of metastatic CRC predictors on treatment outcomes

Smagulova, K.; Kaidarova, Dilyara; Chingissova, Zhanna K.; Nasrytdinov, Timur S.; Khozhayev, Arman

doi:10.1016/j.suronc.2022.101835

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trial results are controversial, resulting in strong interinstitutional differences concerning chemotherapy/targeted therapy sequences for treating patients with mCRC. The optimal cycle numbers of chemotherapy/targeted therapy for metastasectomy for patients with mCRC remains uncertain [26,27].…”

Section: Discussionmentioning

confidence: 99%

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

Yeh¹,

Tsai²,

CHEN³

et al. 2022

View full text Add to dashboard Cite

The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7-20). Clinical outcomes, including response, progression-free survival (PFS), overall survival (OS), and adverse events, were compared between these two groups. Of the 64 patients, 47 (73.4%) were included in the response group, and 17 (26.6%) were included in the nonresponse group. The analysis revealed chemotherapy/targeted therapy cycle and pretreatment serum carcinoembryonic antigen (CEA) level as independent predictors of the response as well as overall survival and chemotherapy/targeted therapy cycle as an independent predictor of progression (all p < 0.05). Furthermore, our results revealed shorter operation time, lower estimated operative blood loss, higher response rate, lower progression rate, and higher survival rate in ≥7 cycles of chemotherapy/ targeted therapy group (all p < 0.05), but no statistical differences in adverse events were observed between the two groups (all p > 0.05). The median OS and PFS were 48 months (95% CI, 40.855-55.145) and 28 months (95% CI, 18.952-37.48) in the ≥7-cycle group and 24 months (95% CI, 22.038-25.962) and 13 months (95% CI, in the 6-cycle group, respectively (both p < 0.001). The oncological outcomes in the ≥7-cycle group were significantly better than those in the 6-cycle group, without significant increases in adverse events. However, prospective randomized trials are mandatory to confirm the potential advantages of cycle numbers of neoadjuvant chemotherapy/targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

Yeh¹,

Tsai²,

CHEN³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…CRC patients typically have microsatellite stability/instability and exhibit long interspersed nuclear elements (LINE-1) hypomethylation and gene sequence variations, including TP53, KRAS, BRAF, and APC 6 – 8 . Currently, the treatment strategies for CRC mainly include neoadjuvant chemotherapy, surgical resection, and targeted therapy, which have favorable effects on CRC 9 – 11 . However, the death rate of CRC remains high for postoperative recurrence and metastasis.…”

Section: Introductionmentioning

confidence: 99%

ATP6AP1 as a potential prognostic biomarker in CRC by comprehensive analysis and verification

Zhang,

Wang,

Zhang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The role of ATP6AP1 in colorectal cancer (CRC) remains elusive despite its observed upregulation in pan-cancer. Therefore, the current study aimed to assess the clinical significance of ATP6AP1 and its relationship with the immune infiltration in CRC. Transcriptome data of CRC were obtained from The Cancer Genome Atlas (TCGA) database and analyzed using the combination of R packages and tumor-related databases, including TIMER2, TISIDB, cBioPortal, and MethSurv. The tissue arrays and immunohistochemical staining were performed to verify the expression and clinical characteristics of ATP6AP1. The results revealed that ATP6AP1 expression was significantly elevated in CRC and associated with poor clinicopathological characteristics and prognosis. Furthermore, the analysis demonstrated ATP6AP1 expression was correlated with the infiltration of immune cells and cancer-associated fibroblasts in the microenvironment of CRC. Moreover, ATP6AP1 was found to be linked to various immune checkpoints and chemokines, with enrichment of cytoplasmic vesicle lumen, endopeptidase regulator activity, and endopeptidase inhibitor activity observed in the high ATP6AP1 expressional group. In conclusion, the findings of this study suggest that ATP6AP1 upregulation may serve as a biomarker for poor diagnosis in CRC and offer a potential target for immunotherapy in CRC.

show abstract

Effects of metastatic CRC predictors on treatment outcomes

Cited by 2 publications

References 14 publications

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

ATP6AP1 as a potential prognostic biomarker in CRC by comprehensive analysis and verification

Contact Info

Product

Resources

About